Yeda's Copaxone — The Best Academic License in History
The Weizmann Institute's tech transfer arm earned more than $1.5bn in royalties on a single multiple sclerosis drug. The structure of that deal is the template Israeli TTOs have spent thirty years trying to replicate.
Copaxone (glatiramer acetate) was synthesized at the Weizmann Institute in the 1960s by Michael Sela, Ruth Arnon, and Dvora Teitelbaum, originally as a research tool for studying autoimmune disease in animal models. It was licensed by Yeda Research and Development — Weizmann's tech transfer arm — to Teva Pharmaceutical Industries, which spent a decade developing it into the world's leading multiple sclerosis therapy. At peak (2014-2015), Copaxone generated more than $4bn in annual Teva revenue. Yeda's royalty take over the drug's commercial life exceeded $1.5bn.
The Copaxone deal is the most lucrative academic license in the history of biomedical research. Its structure — early-stage academic invention, exclusive license to a national-champion industrial partner, royalty stream that runs for decades — is the implicit template every Israeli tech transfer office (TTO) has used since.
Why it's hard to replicate
-
The window. Copaxone's license was negotiated under a 1980s-vintage academic-IP regime. Universities globally now keep more equity and less royalty exposure, partly because the Bayh-Dole framework normalized that pattern.
-
The partner. Teva was the natural Israeli industrial home for an Israeli academic invention. The Israeli pharma sector today is much smaller in terms of national-champion industrial capacity. Most Israeli academic biotech IP now licenses to US or European acquirers, structurally limiting Israeli royalty capture.
-
The molecule. Copaxone benefitted from twenty years of unchallenged patent and a complex generic-substitution path that delayed real biosimilar competition. New molecules don't get this.
What the TTOs actually do today
Yeda, Yissum (Hebrew U), Ramot (TAU), T3 (Technion), and BGN (BGU) have all evolved toward an equity-and-royalty hybrid, with more emphasis on early spinout equity and proof-of-concept funds. The new business model:
- Lower individual deal sizes.
- More deals.
- More portfolio risk-sharing via institutional and government co-investment.
It's a more replicable, more diversified model. It will probably not produce another Copaxone. It will more reliably produce a stream of mid-sized spinouts that anchor the next generation of Israeli scientific founders.